Skip to main content
SpringerLink
Log in

Pediatric Therapeutic Apheresis

  • Chapter
  • First Online:
Pediatric Dialysis

Abstract

The term “apheresis” is derived from a Greek word meaning “removal.” In its most general sense, apheresis refers to techniques for large-scale removal of selected components of the blood. “Plasmapheresis” refers to removal of plasma, “erythrocytapheresis” to removal of red blood cells, and “leukapheresis” to removal of white blood cells. In the first part of this chapter we (SLG, DFF, HCK) will give an overview of apheresis techniques in general as currently practiced in the United States, describe some of the issues that are unique to the application of apheresis techniques in pediatrics, and will review indications for use of apheresis in patients with kidney disease. The latter portion of the chapter (GK) is devoted to an in-depth description of low-density lipoprotein (LDL) apheresis, a specialized application of apheresis technology, as it is currently practiced in Europe.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Nguyen TC, Han YY, Kiss JE, et al. Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med. 2008;36(10):2878–87.

    Article  PubMed  CAS  Google Scholar 

  2. Chopek M, McCullough J. Protein and biochemical changes during plasma exchange. Washington: AABB Press; 1980.

    Google Scholar 

  3. Strauss R, McLeod B. Adverse reactions to therapeutic apheresis. Bethesda: AABB Press; 1996.

    Google Scholar 

  4. Dzik WH, Kirkley SA. Citrate toxicity during massive blood transfusion. Transfus Med Rev. 1988;2(2): 76–94.

    Article  PubMed  CAS  Google Scholar 

  5. Olson PR, Cox C, McCullough J. Laboratory and clinical effects of the infusion of ACD solution during plateletpheresis. Vox Sang. 1977;33(2):79–87.

    Article  PubMed  CAS  Google Scholar 

  6. Szymanski IO. Ionized calcium during plateletpheresis. Transfusion. 1978;18(6):701–8.

    Article  PubMed  CAS  Google Scholar 

  7. Bunchman TE, Maxvold NJ, Barnett J, Hutchings A, Benfield MR. Pediatric hemofiltration: Normocarb dialysate solution with citrate anticoagulation. Pediatr Nephrol. 2002;17(3):150–4.

    Article  PubMed  Google Scholar 

  8. Mair DC, Hirschler N, Eastlund T. Blood donor and component management strategies to prevent transfusion-related acute lung injury (TRALI). Crit Care Med. 2006;34(Suppl 5):S137–43.

    Article  PubMed  CAS  Google Scholar 

  9. Snyder Jr HW, Cochran SK, Balint Jr JP, et al. Experience with protein A-immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura. Blood. 1992;79(9):2237–45.

    PubMed  Google Scholar 

  10. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3–40.

    PubMed  CAS  Google Scholar 

  11. Furst D, Felson D, Thoren G, Gendreau R. Immunoadsorption for the treatment of rheumatoid arthritis: final results of a randomized trial. Prosorba Trial Investigators. Ther Apher. 2000;4(5):363–73.

    Article  PubMed  CAS  Google Scholar 

  12. Hughes LB, Moreland LW. New therapeutic approaches to the management of rheumatoid arthritis. BioDrugs. 2001;15(6):379–93.

    Article  PubMed  CAS  Google Scholar 

  13. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg BM, Nilsson IM. Immunoadsorption for removal of inhibitors: update on treatments in Malmo-Lund between 1980 and 1995. Haemophilia. 1998; 4(1):16–20.

    Article  PubMed  CAS  Google Scholar 

  14. Nilsson IM, Freiburghaus C. Apheresis. Adv Exp Med Biol. 1995;386:175–84.

    Article  PubMed  CAS  Google Scholar 

  15. Uehlinger J, Button GR, McCarthy J, Forster A, Watt R, Aledort LM. Immunoadsorption for coagulation factor inhibitors. Transfusion. 1991;31(3):265–9.

    Article  PubMed  CAS  Google Scholar 

  16. Bohmig GA, Regele H, Saemann MD, et al. Role of humoral immune reactions as target for antirejection therapy in recipients of a spousal-donor kidney graft. Am J Kidney Dis. 2000;35(4):667–73.

    Article  PubMed  CAS  Google Scholar 

  17. Braun N, Kadar JG, Risler T. Therapeutic immunoadsorption – its role in clinical practice. Transfus Sci. 1998;19(Suppl):65–9.

    PubMed  Google Scholar 

  18. Bueno Jr D, Sevigny J, Kaplan AA. Extracorporeal treatment of thrombotic microangiopathy: a ten year experience. Ther Apher. 1999;3(4):294–7.

    Article  PubMed  Google Scholar 

  19. Bygren P, Freiburghaus C, Lindholm T, Simonsen O, Thysell H, Wieslander J. Goodpasture’s syndrome treated with staphylococcal protein A immunoadsorption. Lancet. 1985;2(8467):1295–6.

    Article  PubMed  CAS  Google Scholar 

  20. Dantal J, Bigot E, Bogers W, et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med. 1994;330(1):7–14.

    Article  PubMed  CAS  Google Scholar 

  21. Esnault V, Bignon JD, Testa A, Preud’homme JL, Vergracht A, Soulillou JP. Effect of protein A immunoadsorption on panel lymphocyte reactivity in hyperimmunized patients awaiting a kidney graft. Transplantation. 1990;50(3):449–53.

    Article  PubMed  CAS  Google Scholar 

  22. Esnault VL, Besnier D, Testa A, et al. Effect of protein A immunoadsorption in nephrotic syndrome of various etiologies. J Am Soc Nephrol. 1999;10(9): 2014–17.

    PubMed  CAS  Google Scholar 

  23. Haas M, Bohmig GA, Leko-Mohr Z, et al. Peri-operative immunoadsorption in sensitized renal transplant recipients. Nephrol Dial Transplant. 2002;17(8): 1503–8.

    Article  PubMed  Google Scholar 

  24. Hickstein H, Korten G, Bast R, Barz D, Nizze H, Schmidt R. Immunoadsorption of sensitized kidney transplant candidates immediately prior to surgery. Clin Transplant. 2002;16(2):97–101.

    Article  PubMed  CAS  Google Scholar 

  25. Hiesse C, Kriaa F, Rousseau P, et al. Immunoadsorption of anti-HLA antibodies for highly sensitized patients awaiting renal transplantation. Nephrol Dial Transplant. 1992;7(9):944–51.

    PubMed  CAS  Google Scholar 

  26. Juckett M, Perry EH, Daniels BS, Weisdorf DJ. Hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant. 1991;7(5): 405–9.

    PubMed  CAS  Google Scholar 

  27. Mastrangelo F, Pretagostini R, Berloco P, et al. Immunoadsorption with protein A in humoral acute rejection of kidney transplants: multicenter experience. Transplant Proc. 1995;27(1):892–5.

    PubMed  CAS  Google Scholar 

  28. Matic G, Bosch T, Ramlow W. Background and indications for protein A-based extracorporeal immunoadsorption. Ther Apher. 2001;5(5):394–403.

    Article  PubMed  CAS  Google Scholar 

  29. Mittelman A, Bertram J, Henry DH, et al. Treatment of patients with HIV thrombocytopenia and hemolytic uremic syndrome with protein A (Prosorba column) immunoadsorption. Semin Hematol. 1989;26(2 Suppl 1): 15–18.

    PubMed  CAS  Google Scholar 

  30. Pretagostini R, Berloco P, Poli L, et al. Immunoadsorption with protein A in humoral rejection of kidney transplants. ASAIO J. 1996;42(5): M645–8.

    Article  PubMed  CAS  Google Scholar 

  31. Snyder Jr HW, Mittelman A, Oral A, et al. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer. 1993;71(5):1882–92.

    Article  PubMed  Google Scholar 

  32. Watson PR, Guthrie Jr TH, Caruana RJ. Cisplatin-associated hemolytic-uremic syndrome. Successful treatment with a staphylococcal protein A column. Cancer. 1989;64(7):1400–3.

    Article  PubMed  CAS  Google Scholar 

  33. Parhofer KG, Geiss HC, Schwandt P. Efficacy of different low-density lipoprotein apheresis methods. Ther Apher. 2000;4(5):382–5.

    Article  PubMed  CAS  Google Scholar 

  34. Schmaldienst S, Banyai S, Stulnig TM, et al. Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia. Atherosclerosis. 2000;151(2):493–9.

    Article  PubMed  CAS  Google Scholar 

  35. Vella A, Pineda AA, O’Brien T. Low-density lipoprotein apheresis for the treatment of refractory hyperlipidemia. Mayo Clin Proc. 2001;76(10):1039–46.

    Article  PubMed  CAS  Google Scholar 

  36. Adams DM, Schultz WH, Ware RE, Kinney TR. Erythrocytapheresis can reduce Iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients. J Pediatr Hematol Oncol. 1996;18(1):46–50.

    Article  PubMed  CAS  Google Scholar 

  37. Kim HC, Dugan NP, Silber JH, et al. Erythrocyta­pheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. Blood. 1994;83(4):1136–42.

    PubMed  CAS  Google Scholar 

  38. Stemmler J, Wittmann GW, Hacker U, Heinemann V. Leukapheresis in chronic myelomonocytic leukemia with leukostasis syndrome: elevated serum lactate levels as an early sign of microcirculation failure. Leuk Lymphoma. 2002;43(7):1427–30.

    Article  PubMed  CAS  Google Scholar 

  39. Rowe JM, Lichtman MA. Hyperleukocytosis and leukostasis: common features of childhood chronic myelogenous leukemia. Blood. 1984;63(5):1230–4.

    PubMed  CAS  Google Scholar 

  40. Maurer HS, Steinherz PG, Gaynon PS, et al. The effect of initial management of hyperleukocytosis on early complications and outcome of children with acute lymphoblastic leukemia. J Clin Oncol. 1988; 6(9):1425–32.

    PubMed  CAS  Google Scholar 

  41. Steeper TA, Smith JA, McCullough J. Therapeutic cytapheresis using the Fenwal CS-3000 blood cell separator. Vox Sang. 1985;48(4):193–200.

    Article  PubMed  CAS  Google Scholar 

  42. Benito AI, Gonzalez-Vicent M, Garcia F, et al. Allogeneic peripheral blood stem cell transplantation (PBSCT) from HLA-identical sibling donors in ­children with hematological diseases: a single center pilot study. Bone Marrow Transplant. 2001;28(6): 537–43.

    Article  PubMed  CAS  Google Scholar 

  43. Diaz MA, Garcia-Sanchez F, Lillo R, Vicent MG, Vicario JL, Madero L. Large-volume leukapheresis in pediatric patients: pre-apheresis peripheral blood CD34+ cell count predicts progenitor cell yield. Haematologica. 1999;84(1):32–5.

    PubMed  CAS  Google Scholar 

  44. Goldman JM, Horowitz MM. The international bone marrow transplant registry. Int J Hematol. 2002; 76(Suppl 1):393–7.

    Article  PubMed  Google Scholar 

  45. Gorlin JB, Humphreys D, Kent P, et al. Pediatric large volume peripheral blood progenitor cell collections from patients under 25 kg: a primer. J Clin Apher. 1996;11(4):195–203.

    Article  PubMed  CAS  Google Scholar 

  46. Marson P, Petris MG, Messina C, et al. Peripheral blood stem cell collection in pediatric oncohematology. Experience with patients weighing less than 15 kg. Minerva Pediatr. 2000;52(3):129–35.

    PubMed  CAS  Google Scholar 

  47. Sevilla J, Gonzalez-Vicent M, Madero L, Diaz MA. Peripheral blood progenitor cell collection in low-weight children. J Hematother Stem Cell Res. 2002;11(4):633–42.

    Article  PubMed  Google Scholar 

  48. Torrabadella M, Olive T, Ortega JJ, Massuet L. Enhanced HPC recruitment in children using LVL and a new automated apheresis system. Transfusion. 2000;40(4):404–10.

    Article  PubMed  CAS  Google Scholar 

  49. Collins Jr RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15(2):433–44.

    PubMed  Google Scholar 

  50. Drobyski WR, Hessner MJ, Klein JP, et al. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Blood. 1999;94(2):434–41.

    PubMed  CAS  Google Scholar 

  51. Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood. 1993;82(8):2310–18.

    PubMed  CAS  Google Scholar 

  52. Gasparetto C, Gasparetto M, Morse M, et al. Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF. Cytokine. 2002;18(1):8–19.

    Article  PubMed  CAS  Google Scholar 

  53. Mandanas RA, Saez RA, Selby GB, Confer DL. G-CSF-mobilized donor leukocyte infusions as immunotherapy in acute leukemia relapsing after allogeneic marrow transplantation. J Hematother. 1998;7(5):449–56.

    Article  PubMed  CAS  Google Scholar 

  54. Zic JA, Miller JL, Stricklin GP, King Jr LE. The North American experience with photopheresis. Ther Apher. 1999;3(1):50–62.

    Article  PubMed  CAS  Google Scholar 

  55. Rook AH, Suchin KR, Kao DM, et al. Photopheresis: clinical applications and mechanism of action. J Investig Dermatol Symp Proc. 1999;4(1):85–90.

    Article  PubMed  CAS  Google Scholar 

  56. Knobler R, Jantschitsch C. Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma. Transfus Apher Sci. 2003;28(1):81–9.

    Article  PubMed  CAS  Google Scholar 

  57. Knobler R, Girardi M. Extracorporeal photochemoimmunotherapy in cutaneous T cell lymphomas. Ann N Y Acad Sci. 2001;941:123–38.

    Article  PubMed  CAS  Google Scholar 

  58. Knobler R. Extracorporeal photochemotherapy – Present and future. Vox Sang. 2000;78(Suppl 2): 197–201.

    PubMed  Google Scholar 

  59. Greinix HT, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood. 1998;92(9):3098–104.

    PubMed  CAS  Google Scholar 

  60. Shinoda T. Photopheresis and leukocytapheresis: cytapheresis treatment against immune-mediated diseases. Ther Apher. 2002;6(4):245–6.

    Article  PubMed  Google Scholar 

  61. Schneider M. Plasma- and lymphapheresis in autoimmune diseases. Z Rheumatol. 1996;55(2):90–104.

    PubMed  CAS  Google Scholar 

  62. Costanzo-Nordin MR, Hubbell EA, O’Sullivan EJ, et al. Photopheresis versus corticosteroids in the therapy of heart transplant rejection. Preliminary clinical report. Circulation. 1992;86(Suppl 5):II242–50.

    PubMed  CAS  Google Scholar 

  63. Meiser BM, Kur F, Reichenspurner H, et al. Reduction of the incidence of rejection by adjunct immunosuppression with photochemotherapy after heart transplantation. Transplantation. 1994;57(4):563–8.

    PubMed  CAS  Google Scholar 

  64. Rossetti F, Dall’Amico R, Crovetti G, et al. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Bone Marrow Transplant. 1996;18(Suppl 2):175–81.

    PubMed  Google Scholar 

  65. Dall’Amico R, Rossetti F, Zulian F, et al. Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease. Br J Haematol. 1997;97(4): 848–54.

    Article  PubMed  Google Scholar 

  66. Adami R. Therapeutic thrombocytapheresis: a review of 132 patients. Int J Artif Organs. 1993;16(Suppl 5):183–4.

    PubMed  Google Scholar 

  67. Baron BW, Mick R, Baron JM. Combined plateletpheresis and cytotoxic chemotherapy for symptomatic thrombocytosis in myeloproliferative disorders. Cancer. 1993;72(4):1209–18.

    Article  PubMed  CAS  Google Scholar 

  68. Liumbruno G, Centoni PE, Ceretelli S, Sodini ML. Rapid reduction of platelet numbers in thrombocytosis. Ther Apher. 2000;4(5):374–6.

    Article  PubMed  CAS  Google Scholar 

  69. Renner D, Queisser U, Martinez C, Queisser W. Treatment of excessive thrombocythemia in chronic myeloid leukemia by thrombocytopheresis and intravenous Thio-TEPA. Onkologie. 1987;10(5):324–6.

    Article  PubMed  CAS  Google Scholar 

  70. Ullrich H, Kadar J, Waxenberger Y, et al. Therapeutic thrombocytapheresis in patients with myeloproliferative diseases with the cell separators Fresenius AS 104 and Cobe Spectra: biocompatibility and safety. Beitr Infusionsther. 1992;30:311–14.

    PubMed  CAS  Google Scholar 

  71. Gerhardt RE, Ntoso KA, Koethe JD, Lodge S, Wolf CJ. Acute plasma separation with hemodialysis equipment. J Am Soc Nephrol. 1992;2(9):1455–8.

    PubMed  CAS  Google Scholar 

  72. Price CA. Therapeutic plasma exchange in a dialysis unit. ANNA J. 1987;14(2):103–8.

    Article  PubMed  CAS  Google Scholar 

  73. Nadler S, Hidalgo J, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962;51:224.

    PubMed  Google Scholar 

  74. Kim HC. Therapeutic pediatric apheresis. J Clin Apher. 2000;15(1–2):129–57.

    Article  PubMed  CAS  Google Scholar 

  75. Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice – Evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25(3): 83–177.

    Article  PubMed  Google Scholar 

  76. Owen HG, Brecher ME. Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis. Transfusion. 1994;34(10):891–4.

    Article  PubMed  CAS  Google Scholar 

  77. Thompson GR. LDL apheresis. Atherosclerosis. 2003;167(1):1–13. Review.

    Article  PubMed  CAS  Google Scholar 

  78. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003;168(1):1–14. Review.

    Article  PubMed  CAS  Google Scholar 

  79. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986; 232(4746):34–47. Review.

    Article  PubMed  CAS  Google Scholar 

  80. Leigh SE, Foster AH, Whittall RA, Hubbart CS, Humphries SE. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann Hum Genet. 2008;72(Pt 4):485–98.

    Article  PubMed  CAS  Google Scholar 

  81. Masaki N, Tatami R, Kumamoto T, Izawa A, Shimada Y, Takamatsu T, Katsushika S, Ishise S, Maruyama Y, Yoshimoto N. Ten-year follow-up of familial hypercholesterolemia patients after intensive cholesterol-lowering therapy. Int Heart J. 2005;46(5): 833–43.

    Article  PubMed  Google Scholar 

  82. Coker M, Ucar SK, Simsek DG, Darcan S, Bak M, Can S. Low density lipoprotein apheresis in pediatric patients with homozygous familial hypercholesterolemia. Ther Apher Dial. 2009;13(2):121–8.

    Article  PubMed  CAS  Google Scholar 

  83. Mabuchi H, Koizumi J, Shimizu M, Kajinami K, Miyamoto S, Ueda K, Takegoshi T. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol. 1998;82(12):1489–95.

    Article  PubMed  CAS  Google Scholar 

  84. Stefanutti C, Vivenzio A, Di Giacomo S, Mazzarella B, Bosco G, Berni A. Aorta and coronary angiographic follow-up of children with severe hypercholesterolemia treated with low-density lipoprotein apheresis. Transfusion. 2009;49(7):1461–70. Epub 2009 Mar 23.

    Article  PubMed  CAS  Google Scholar 

  85. Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, Parekh RS, Steinberger J; American Heart Association Expert Panel on Population and Prevention Science; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Nutrition, Physical Activity and Metabolism; American Heart Association Council on High Blood Pressure Research; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on the Kidney in Heart Disease; Interdisciplinary Working Group on Quality of Care and Outcomes Research. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2006;114(24):2710–38. Epub 2006 Nov 27. Review.

    Google Scholar 

  86. Palcoux JB, Atassi-Dumont M, Lefevre P, Hequet O, Schlienger JL, Brignon P, Roussel B. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther Apher Dial. 2008;12(3):195–201.

    Article  PubMed  CAS  Google Scholar 

  87. Böhler J, Schollmeyer P, Dressel B, Dobos G, Hörl WH. Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophil degranulation. J Am Soc Nephrol. 1996;7(2):234–41.

    PubMed  Google Scholar 

  88. Gabutti L, Ferrari N, Mombelli G, Keller F, Marone C. The favorable effect of regional citrate anticoagulation on interleukin-1beta release is dissociated from both coagulation and complement activation. J Nephrol. 2004;17(6):819–25.

    PubMed  CAS  Google Scholar 

  89. Stefanutti C, Di Giacomo S, Vivenzio A, Colloridi V, Bosco G, Berni A, Rabbone I, Cerutti F, Bertolini S. Low-density lipoprotein apheresis in a patient aged 3.5 years. Acta Paediatr. 2001;90(6):694–701.

    Article  PubMed  CAS  Google Scholar 

  90. Hudgins LC, Kleinman B, Scheuer A, White S, Gordon BR. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol. 2008;102(9):1199–204.

    Article  PubMed  CAS  Google Scholar 

  91. De Silvestro G, Tison T, Vicarioto M, Bagatella P, Stefanutti C, Marson P. The Italian Registry of Pediatric Therapeutic Apheresis: a report on activity during 2005. J Clin Apher. 2009;24(1):1–5.

    Article  PubMed  Google Scholar 

  92. Soufi M, Kurt B, Schweer H, Sattler AM, Klaus G, Zschocke J, Schaefer JR. Genetics and kinetics of familial hypercholesterolemia, with the special focus on FH-Marburg).W556R. Atheroscler Suppl. 2009; 10(5):5–11.

    Article  PubMed  CAS  Google Scholar 

  93. Geiss HC, Parhofer KG, Donner MG, Schwandt P. Low density lipoprotein apheresis by membrane differential filtration (cascade filtration). Ther Apher. 2000;3(3):199–202.

    Google Scholar 

  94. Seidel D, Armstrong VW, Schuff-Werner P. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the ­secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months. HELP Study Group. Eur J Clin Invest. 1991;21(4):375–83.

    Article  PubMed  CAS  Google Scholar 

  95. Bosch T, Gahr S, Belschner U, Schaefer C, Lennertz A, Rammo J, for the DALI Study Group. Direct adsorption of low-density lipoprotein by DALI-LDL-apheresis: results of a prospective long-term multicenter follow-up covering 12,291 sessions. Ther Apher Dial. 2006;10(3):210–18.

    Article  PubMed  CAS  Google Scholar 

  96. Uauy R, Zwiener RJ, Phillips MJ, Petruska ML, Bilheimer DW. Treatment of children with homozygous familial hypercholesterolemia: safety and efficacy of low-density lipoprotein apheresis. J Pediatr. 1992;120(6):892–8.

    Article  PubMed  CAS  Google Scholar 

  97. Zwiener RJ, Uauy R, Petruska ML, Huet BA. Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia. J Pediatr. 1995;126(5 Pt 1):728–35.

    PubMed  CAS  Google Scholar 

  98. Eminoglu TF, Yenicesu I, Tumer L, Okur I, Dilsiz G, Hasanoglu A. Lipid apheresis applications in childhood: experience in the University Hospital of Gazi. Transfus Apher Sci. 2008;39(3):235–40.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of Cincinnati College of Medicine, Division of Nephrology and Hypertension & The Heart Institute, Cincinnati, OH, 45229, USA

    Stuart L. Goldstein MD

  2. Center for Acute Care Nephrology, Pheresis Service, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, MLC 7022, Cincinnati, OH, 45229, USA

    Stuart L. Goldstein MD

  3. Pediatric Kidney Center, KfH-Kuratorium fur Dialyse und Nierentransplantation, Marburg, Germany

    Gunter Klaus MD

  4. Transfusion Service and Apheresis Service, Philadelphia, USA

    David F. Friedman MD (Associate Medical Director)

  5. Phlebotomy Service, Children’s Hospital of Pennsylvania, Philadelphia, PA, USA

    David F. Friedman MD (Medical Director)

  6. Apheresis Service, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Haewon C. Kim MD (Medical Director)

  7. Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

    Haewon C. Kim MD (Medical Director)

Authors
  1. Stuart L. Goldstein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gunter Klaus MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David F. Friedman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David F. Friedman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Haewon C. Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stuart L. Goldstein MD .

Editor information

Editors and Affiliations

  1. Children’s Mercy Hospital and Clinics, Department of Pediatrics, Section of Pediatric Nephrology, School of Medicine, Kansas City, 64108, Missouri, USA

    Bradley A. Warady

  2. Center for Pediatrics, and Adolescent Medicine, Division of Pediatric Nephrology, Im Neuenheimer Feld 150, Heidelberg, 69120, Germany

    Franz Schaefer

  3. Department of Pediatrics, Stanford University School of Medicine, Division of Pediatric Nephrology, Welch Road 770, Palo Alto, 94304, California, USA

    Steven R. Alexander

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Goldstein, S.L., Klaus, G., Friedman, D.F., Friedman, D.F., Kim, H.C. (2012). Pediatric Therapeutic Apheresis. In: Warady, B., Schaefer, F., Alexander, S. (eds) Pediatric Dialysis. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-0721-8_41

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-0721-8_41

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-0720-1

  • Online ISBN: 978-1-4614-0721-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation